BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 34735635)

  • 1. Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients.
    Ferrucci PF; Lens M; Cocorocchio E
    Curr Oncol Rep; 2021 Nov; 23(12):138. PubMed ID: 34735635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
    Kiniwa Y; Okuyama R
    Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
    Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
    Giugliano F; Crimini E; Tarantino P; Zagami P; Uliano J; Corti C; Trapani D; Curigliano G; Ascierto PA
    Cancer Treat Rev; 2021 Sep; 99():102253. PubMed ID: 34186441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
    Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
    Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
    Delyon J; Lebbe C; Dumaz N
    Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
    Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
    Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.
    Trojaniello C; Sparano F; Cioli E; Ascierto PA
    Curr Oncol Rep; 2023 Jun; 25(6):623-634. PubMed ID: 36995534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck.
    Wilson MA; Fecher LA
    Otolaryngol Clin North Am; 2021 Apr; 54(2):329-342. PubMed ID: 33602512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Schummer P; Schilling B; Gesierich A
    Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.